


trifuge in years. It features an advanced sealed rotor design that combines exceptional ease of use with excellent cell recovery.

Many other design innovations make the programmable Cytopro system remarkably versatile, safe, and userfriendly. Consistent results, economically achieved. That's what to expect from the Cytopro system.

The Cytopro system not only works well in cytology, hematology and microbiology, but with any application involving cell suspensions. Any staining system may be used.

So forget the past and try today's cytocentrifuge. To arrange a demonstration or to receive more information, contact Wescor, Inc., 459 South Main Street, Logan, UT, 84321 USA. Toll-free **1-800-453-2725.** FAX 801-752-4127.



# **Dioxin Exposure**

In Richard Stone's 10 September article "New Seveso findings point to cancer" (News & Comment, p. 1383), it is reported that I speculated that "some other carcinogenic compound in the Seveso cloud . . . may have been responsible for the elevated cancer risk." However, my comments about the possibility of other carcinogens causing some of the elevated cancer rates associated with dioxin specifically addressed the findings in the National Institute of Occupational Safety and Health (NIOSH) Dioxin Registry (1) and not the Seveso accident. In discussing the findings of the NIOSH Dioxin Registry, I and my co-investigators have written that consideration of potential confounders such as other occupational exposures, smoking, and failure to control for regional variation in the general population cancer mortality are important for evaluating the potential cancer risk for any substance, including dioxin (2). A study we recently completed indicates that considering other occupational exposure, such as 4-aminobiphenyl, may be important for evaluating the cancer findings of soft tissue sarcoma in the NIOSH Dioxin Registry (3).

Insofar as the Seveso study is concerned, we believe it is too early to determine whether the findings of Seveso are consistent with those of the NIOSH Dioxin Registry. All the increases in cancer incidence in the NIOSH Dioxin Registry occurred 20 or more years after exposure, while the Seveso study reports on people exposed only 10 years ago. We agree with Pier Alberto Bertazzi's statement that "[t]his is not the final word from Seveso." James J. Collins

Director of Epidemiology, Monsanto Company, St. Louis, MO 63167

### References

- 1. M. A. Fingerhut *et al.*, *N. Engl. J. Med.* **324**, 21 (1991).
- 2. J. J. Collins, J. F. Acquavella, B. R. Friedlander, *Epidemiology* **3**, 65 (1992).
- 3. J. J. Collins, M. E. Strauss, G. J. Levinskas, P. R. Conner, *ibid.* 4, 7 (1993).

## Genetics and Crime

In describing my opposition to renewed funding of the "Genetic Factors and Crime" conference at the University of Maryland, Eliot Marshall writes ("NIH told to reconsider crime meeting," News & Comment, 1 Oct., p. 23) that I "claimed the conference was a part of a scheme to pacify unruly people with psychoactive chemicals." This characterization seems to misrepresent my concerns.

The conference brochure specifically advocated genetic and biological theories for the causation of violent crime and looked forward

SCIENCE • VOL. 262 • 3 DECEMBER 1993

to the treatment of "predisposed" individuals with "drugs." Since there are no known biological or genetic factors that contribute to violent crime, and no drug treatments, it would have been highly misleading, potentially racist, and politically menacing for the federal government and the state of Maryland to fund the conference. Many others agreed, especially leaders in the African-American community. We also believe that biomedical social control is a threat to fundamental values, such as liberty, due process, respect for the individual, and community.

While our efforts helped to temporarily stop the Maryland conference and compelled the federal government to reject the most overt aspects of a planned violence initiative, many expressions of the initiative remain in place in several health agencies and the Department of Justice. These include mammoth federal funding for the biomedical control of "disruptive" children, as well as research aimed at identifying biological and genetic factors in supposedly violence-prone children and adults.

> Peter R. Breggin Center for the Study of Psychiatry, 4628 Chestnut Street, Bethesda, MD 20814

### A Life-Saving Accelerator

The article by Fred Myers about the heavy ion medical accelerator being built in Japan (News & Comment, 3 Sept., p. 1270) was of special interest to me. I was one of the last cancer patients to receive radiation therapy at the Heavy-Ion Linear Accelerator (HILAC) facility at Lawrence Berkeley Laboratory (LBL) before it was shut down last June. Without the LBL facility, I would have been unable to obtain treatment anywhere in the world. My tumor was behind my left eye and in an interior sinus cavity, and it required extensive surgery: a frontal craniotomy. The radiation had to be deposited in a very small volume to avoid doing too much damage to optic nerves and the pituitary gland and to avoid irradiating sensitive areas that had previously received massive radiation for a previous cancer.

Although the radiation caused complete loss of vision in my left eye and affected the function of my pituitary gland, my doctors and I have no doubt that my life was prolonged for a significant period by the treatment.

The decision to shut down the LBL facility was made jointly by the Department of Energy and the National Aeronautics and Space Administration. I made an effort to communicate with officials about the value of the facility. My impression is that the decisionmakers considered its medical applications to